Tommy sells INCY 106.62: JPMorgan Chase & Co. reiterated an overweight rating and issued a $111.00 price objective on shares of Incyte in a research report on Sunday, May 24th.

Aduro's CRS-207 has been shown to stimulate immune cell activity, with particular targeting mechanisms that seek and attack tumor cells that express mesothelin like those found in ovarian cancer. The combination of both investigational immunotherapeutic agents, which have different but complementary mechanisms directed at enhancing the body's own immune defenses, may provide unique synergies in fighting cancer. Finally, Cowen and Company restated an outperform rating on shares of Incyte in a report on Wednesday, July 22nd. They issued a buy rating and a $126.00 price objective for the company. Bank of America began coverage on shares of Incyte in a research note on Friday, May 29th.


Hye:
INCY has been the topic of several other reports.

Obdulia:
The biopharmaceutical company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.06. During the same quarter in the previous year, the company posted ($0.22) earnings per share.

Janna:
Incyte ( NASDAQ:INCY ) opened at 116.07 on Monday.

Aimee:
Hengrui's products and innovative R&D span multiple therapeutic areas, including oncology and hematology, anesthesiology and pain management, cardiovascular and metabolic diseases, contrast media, and inflammation.

Eveline:
Jiangsu Hengrui Medicine Co., Ltd., established in 1970, is a fully integrated pharmaceutical company in China, with annual net sales of over U.S. $1.2 billion.

Dusty:
About Incyte Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology.

Daisey:
Many tumor cells express PD-L1, an immunosuppressive PD-1 ligand.

Amberly:
About Anti-PD-1 Monoclonal Antibodies Monoclonal antibodies targeting PD-1 enhance anti-tumoral immunity and are being developed for the treatment of cancer.

Olga:
Under the Agreement, Incyte and Hengrui will assume all financial obligations associated with the development and commercialization of SHR-1210 in their respective territories.

Elizabeth:
The terms also include tiered royalties to Hengrui on net sales of SHR-1210 in Incyte territories.

Incyte Corp. (NASDAQ:INCY)
//stockhand.net/us/?q=nasdaq%3Aincy&id=421730